|Bid||2.85 x 3200|
|Ask||3.65 x 1000|
|Day's Range||3.08 - 3.27|
|52 Week Range||2.93 - 4.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
While Therapy revenue was just about dead-on with what we had been expecting, Detection revenue was quite disappointing. Detection revenue was 15% lower than where we thought it would come in, with almost all of the miss related to product sales. While we had anticipated Detection revenue would contract sequentially given some lumpiness in Q4 ’17, we did think tomo-related momentum would result in solid double-digit yoy growth in product sales in that segment.
The Nashua, New Hampshire-based company said it had a loss of 20 cents per share. Losses, adjusted for severance costs and non-recurring costs, were 19 cents per share. The imaging and early cancer detection ...
iCAD Inc (NASDAQ:ICAD) is a small-cap stock with a market capitalization of US$62.32M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...
Revenue, particularly in the Detection segment, continued to impress with very strong sales of the tomo (2D and 3D) products pushing total revenue up by 14% yoy. Detection product sales, up 100% yoy (pro-forma for ex-MRI), turned in the best quarter since Q3 2011 (when ICAD was still direct-selling MRI software) and crushed our number by 25%. While Q4 is typically ICAD’s strongest, the apparent accelerating adoption of the ‘legacy’ 2D and first-gen 3D tomo (GE-only) applications is obviously encouraging, particularly given the near-term launch of ICAD’s next-gen software.
The Dow Jones Industrial Average dropped more than 700 points on a down day for U.S. equities in which President Donald Trump announced tariffs on international imports from China. The index fell 2.9% Thursday, while the S&P 500 Index fell 2.5% and the Nasdaq Composite fell 2.4%.
By Brian Marckx, CFA NASDAQ:ICAD Decision-Tree Analysis of Published Studies Indicates IORT Superior To EBRT in QoL, Cost: A study which was recently published in Cost Effectiveness and Resource Allocation ...
While small-cap stocks, such as iCAD Inc (NASDAQ:ICAD) with its market cap of USD $58.45M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
By Brian Marckx, CFA NASDAQ:ICAD Q3 2017 Results: Revenue Dead-On With Our Estimate. Solid Results From Both Detection and Therapy… iCAD (NASDAQ:ICAD) reported Q3 financial results for their third quarter ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to iCAD, Inc. Here are 5 ETFs with the largest exposure to ICAD-US. Comparing the performance and risk of iCAD, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis iCAD, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of iCAD, Inc. – Royal Philips NV Sponsored ADR, Hologic, Inc., General Electric Company, Varian Medical Systems, Inc. and Digirad Corporation (PHG-US, HOLX-US, GE-US, VAR-US and DRAD-US) that have also ... Read more (Read more...)
By Brian Marckx, CFA NASDAQ:ICAD Q2 2017 Results: Results Much More Solid Than Numbers Suggest. U.S. Tomo Launch Encouraging iCAD (NASDAQ:ICAD) reported results for their second quarter ending June 30th. ...
Categories: Yahoo FinanceGet free summary analysis iCAD, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of iCAD, Inc. – Fonar Corporation, Royal Philips NV Sponsored ADR, Hologic, Inc., General Electric Company, Varian Medical Systems, Inc. and Digirad Corporation (FONR-US, PHG-US, HOLX-US, GE-US, VAR-US and DRAD-US) ... Read more (Read more...)